全球醫藥成分市場:按合成、按效力、按製造商、按類型、按藥物、按應用、按地區、機會、預測,2017-2031 年
市場調查報告書
商品編碼
1422069

全球醫藥成分市場:按合成、按效力、按製造商、按類型、按藥物、按應用、按地區、機會、預測,2017-2031 年

Active Pharmaceutical Ingredient Market Assessment, By Synthesis, By Potency, By Manufacturer, By Type, By Drug, By Usage, By Application, By Region, Opportunities and Forecast, 2017-2031F

出版日期: | 出版商: Market Xcel - Markets and Data | 英文 217 Pages | 商品交期: 3-5個工作天內

價格

2023年全球活性藥物成分市場規模為2,117.5億美元,預計2031年將達3,693億美元,2024-2031年預測期內複合年增長率為7.2%,預計將成為。全球活性藥物成分市場受到藥品需求增加、慢性病盛行率增加、生物技術和生物製藥廣泛採用、仿製藥市場蓬勃發展以及人工智慧等技術進步等因素的影響。

全球活性藥物成分市場是製藥業的基本支柱,為改善和維持全球健康標準所需的關鍵藥品的配方和製造提供所需的基本成分。隨著醫療保健領域不斷發展,活性藥物成分(API)市場的重要性日益凸顯。全球藥物活性成分市場主要由以印度和中國為首的亞太地區推動,受益於成本優勢和高技能勞動力。相較之下,北美和歐洲仍然是重要的原料藥消費者,這主要是由於其蓬勃發展的製藥業。

全球活性藥物成分市場受到藥品需求不斷增長的顯著影響,這在很大程度上是由人口老化和新興市場努力改善醫療保健機會所推動的。生物技術和生物製藥的使用正在增加對生物衍生藥物的需求,主要是因為它們獨特而精確的治療應用。隨著重磅藥物專利到期,仿製藥產業仍然活躍,並嚴重依賴 API 進行具有成本效益的生產。同時,人工智慧(AI)和其他技術的進步將徹底改變藥品研發和生產,使原料藥更有效率、更具成本效益,進而帶動全球活性藥物成分市場的成長。

該報告調查了全球藥物原料藥市場,並提供了市場概述,以及按合成、功效、製造商、類型、藥物、應用、地區和進入市場的公司概況等劃分的趨勢。

目錄

第一章研究方法論

第二章 專案範圍與定義

第三章執行摘要

第四章 2017-2031年全球原料藥市場展望

  • 市場規模及預測
  • 按成分分類
  • 按效價
  • 按製造商
  • 按類型
  • 透過藥物
  • 按用途
  • 按地區
  • 按公司劃分的市佔率 (%),2023 年

第五章 2017-2031 年全球醫藥原料市場展望(按地區)

  • 北美
  • 歐洲
  • 南美洲
  • 亞太地區
  • 中東/非洲

第 6 章 市場測繪,2023 年

第七章 宏觀環境與產業結構

  • 供需分析
  • 進出口分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第八章市場動態

第九章 監理架構與創新

第十章 主要與企業狀況

第11章價格分析

第十二章案例研究

第十三章 主要公司展望

  • Pfizer, Inc
  • Abbvie, Inc.
  • Novartis AG
  • Sanofi S.A.
  • F. Hoffmann-La Roche AG
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • GlaxoSmithKline plc.
  • AstraZeneca plc
  • Eli Lilly International Corp.
  • Teva Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim International GmbH
  • Johnson & Johnson Services, Inc.

第十四章 戰略建議

第十五章 查詢及免責聲明

Product Code: MX10934

Global active pharmaceutical ingredient market size was valued at USD 211.75 billion in 2023, expected to reach USD 369.3 billion in 2031, with a CAGR of 7.2% for the forecast period between 2024 and 2031F. The global active pharmaceutical ingredient market is influenced by factors such as rising pharmaceutical demand, growing incidence of chronic illnesses, widespread adoption of biotechnology and biopharmaceuticals, thriving market for generic drugs, and advancements in technologies like artificial intelligence.

The global active pharmaceutical ingredient market functions as the fundamental pillar of the pharmaceutical sector, providing the essential components required for the formulation and manufacturing of crucial medicines, which are indispensable for enhancing and maintaining global health standards. With the healthcare landscape evolving continuously, the active pharmaceutical ingredient (API) market's significance grows more pronounced. The global active pharmaceutical ingredient market is predominantly led by Asia-Pacific, with India and China at the forefront, benefiting from cost advantages and a highly skilled workforce. In contrast, North America and Europe remain significant API consumers, largely due to their thriving pharmaceutical industries.

Global active pharmaceutical ingredient market is greatly influenced by rising demand for pharmaceuticals, largely driven by aging populations and emerging markets striving to improve healthcare accessibility. The utilization of biotechnology and biopharmaceuticals has amplified the request for biologically derived APIs, primarily due to their inventive and precise therapeutic applications. The expiration of patents for blockbuster drugs continues to energize the generic drug sector, which heavily depends on APIs to achieve cost-effective production. Meanwhile, artificial intelligence (AI) and other technological advancements are ushering in a transformation in drug research, development, and production, enhancing the efficiency and cost-effectiveness of APIs, leading to growth in the global active pharmaceutical ingredient market.

Increasing Global Demand for Pharmaceuticals

Shifting demographics, particularly the aging of populations across various regions, contribute significantly to the heightened need for healthcare interventions, consequently driving pharmaceutical demand upwards. Additionally, the rising prevalence of chronic diseases, often linked to shifts in lifestyle and urbanization, amplifies the requirement for medications aimed at managing and treating these health issues. With expanding economies and improved healthcare accessibility, more individuals can afford and access essential medications, thereby further stimulating the global pharmaceutical market.

Furthermore, the persistent pursuit of groundbreaking therapies and treatments, coupled with the rapid expansion of biotechnology and personalized medicine, sustains a continuous demand for pharmaceutical products. The demand encompasses traditional drugs and extends to biopharmaceuticals and novel therapeutic approaches, thus broadening the pharmaceutical market's scope. In essence, the mounting global demand for pharmaceuticals results from an intricate interplay among demographic, economic, and technological factors, with healthcare requirements standing as the central driver of the burgeoning trend.

Technological Progress is Propelling the Market Forward

Breakthroughs in cutting-edge technologies like Artificial Intelligence (AI) and Machine Learning (ML) are instigating a profound transformation in the production of active pharmaceutical ingredients (APIs). Within the global active pharmaceutical ingredient market, AI and ML systems are increasingly harnessed for their capacity to streamline processes, minimize errors, and augment operational efficiency. These innovations enable real-time monitoring and predictive analytics, thereby facilitating manufacturers in maintaining consistent quality and yield standards. By scrutinizing extensive datasets and recognizing underlying patterns, AI and ML algorithms contribute to developing more effective and precise production methodologies that indirectly boost the global active pharmaceutical ingredient market.

As an incidence of AI and ML's impact, a recent study, featured in a publication of May 2023 of Nature Communications, authored by MIT and Takeda researchers, introduced a groundbreaking approach that combines physics principles with machine learning to classify the irregular surfaces characterizing particles within mixtures. Employing a physics-enhanced autocorrelation-based estimator (PEACE), the technique can potentially revolutionize pharmaceutical manufacturing processes for tablets and powders. It promises heightened efficiency, precision, and a reduction in the occurrence of failed batches, thereby elevating the overall productivity and accuracy of pharmaceutical product manufacturing.

Government Initiatives

Governments worldwide are implementing a range of strategies to attain self-reliance in active pharmaceutical ingredient (API) production, boosting growth in the global active pharmaceutical ingredient market. The strategic endeavor stems from acknowledging the pivotal role APIs play in ensuring a steady supply of essential medications, particularly during global crises, like the COVID-19 pandemic. Governments are actively promoting the growth of domestic API manufacturing capabilities to reduce reliance on foreign sources, fortify national healthcare security, and mitigate potential vulnerabilities in the supply chain. These efforts often encompass investments in research and development, providing incentives for domestic production, streamlining regulatory procedures, and fostering collaboration between public and private sectors to bolster the resilience and capacity of domestic API production.

For instance, in March 2023, a minister of Canada unveiled a federal investment initiative to boost the country's capability to research and produce essential medications. The initiative, backed by over USD 80.5 million in federal funding and based in Edmonton, will empower emerging pharmaceutical companies to introduce new products to the market and cultivate talent in Alberta's life sciences sector. The Canadian Critical Drug Initiative is designed to augment Canada's manufacturing capacity and supply chain, thus reducing the nation's reliance on foreign sources for active pharmaceutical ingredients. Simultaneously, it supports the commercialization of crucial medicines, contributing to healthcare self-sufficiency.

High Demand for HPAPIs

The demand for High Potency Active Pharmaceutical Ingredients (HPAPIs) is substantial in the global active pharmaceutical ingredient market due to their pivotal role in pharmaceutical formulations. Approximately one-quarter of pharmaceutical drugs worldwide feature HPAPIs, recognized for their exceptional effectiveness. HPAPIs are compounds that demonstrate potent pharmacological activity at low concentrations, making them indispensable for addressing intricate health conditions like cancer and autoimmune disorders. Their precision and strength enable precise therapeutic targeting, reducing adverse effects while optimizing treatment outcomes.

Given their fundamental contribution to contemporary healthcare, the demand for HPAPIs remains robust, as researchers and pharmaceutical firms continuously explore their potential for innovating advanced and highly efficacious medicines. For instance, in July 2023, Evonik and Heraeus Precious Metals joined hands to broaden their respective portfolios of services pertaining to highly potent active pharmaceutical ingredients (HPAPIs). The collaboration harnesses unique HPAPI expertise of both firms to deliver a comprehensive solution, spanning from the early preclinical phases to full-scale commercial production. The integrated offering includes a seamless transition between small-scale and large-scale manufacturing processes, enabling a more efficient and versatile approach to HPAPI development and production.

Growing Demand for Therapeutic Enzymes

The global active pharmaceutical ingredient market is witnessing a notable increase in the demand for APIs that rely on enzymes. Enzymes are crucial in formulating pharmaceuticals by facilitating targeted drug delivery and improving therapeutic effectiveness. The upsurge in demand is driven by several factors, including the growing adoption of biotechnology in drug research, the emergence of precision medicine, and the pharmaceutical industry's increasing emphasis on sustainable and eco-friendly manufacturing practices. Enzyme-based APIs offer significant benefits like precise action, reduced side effects, and environmentally conscious production methods. Consequently, they have become an essential component in developing cutting-edge pharmaceuticals, effectively addressing both therapeutic requirements and sustainability objectives within the evolving pharmaceutical sector. For instance, in October 2022, Gingko Bioworks unveiled a partnership with Merck, with the goal of enhancing the production of active pharmaceutical ingredients. The initiative involves the genetic engineering of potentially four enzymes to serve as biocatalysts in Merck's API production endeavors.

Future Market Scenario

The global active pharmaceutical ingredient market's future is characterized by optimistic growth prospects driven by several key factors. To begin with, the pharmaceutical industry's dedication to innovation and substantial investments in research and development are poised to stimulate the demand for specialized APIs. The trend is particularly pertinent as pursuing precision medicine and targeted therapies gains traction, necessitating novel APIs with unique attributes.

Additionally, sustainability will be pivotal in shaping the API market's trajectory. The adoption of green chemistry practices and eco-friendly production methods aligns with global environmental initiatives and resonates with a growing number of environmentally conscious consumers and regulatory bodies. Furthermore, cultivating international collaborations and partnerships will provide access to diverse markets and resources, thereby augmenting the API market's growth potential. To summarize, the bright future of the API market hinges on innovation, sustainability, regulatory compliance, and robust supply chain strategies.

Key Players Landscape and Outlook

Prominent pharmaceutical firms are progressively joining forces to produce APIs. The cooperative initiative is geared towards boosting operational efficiency, cost reduction, and expediting the creation of vital drugs. These corporations can consolidate their capabilities, simplify manufacturing procedures, and secure a consistent API supply through the exchange of resources, research findings, and expertise.

Furthermore, such partnerships help them lessen the vulnerabilities linked to depending solely on one supplier, thus reinforcing their adaptability when confronted with unexpected difficulties. Ultimately, these collaborations play a crucial role in advancing the global active pharmaceutical ingredient market, ensuring the availability of essential medications, and improving patient access to life-saving treatments.

A recent example involved the cooperation of four companies in July 2022, to offer a dedicated service for the rapid development of mobile units for API production, known as the Production Intelligente de Principes Actifs (PIPAc) project. The initiative aims to streamline the complex and lengthy supply chains associated with API production. PIPAc encompasses synthesis, continuous flow chemistry, in-flow analysis, and leverages artificial intelligence (AI) to design efficient production units equipped with autonomous capabilities.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Active Pharmaceutical Ingredient Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. Value
    • 4.1.2. Volume
  • 4.2. By Synthesis
    • 4.2.1. Biotech
      • 4.2.1.1. Monoclonal Antibodies
      • 4.2.1.2. Hormones
      • 4.2.1.3. Cytokines
      • 4.2.1.4. Recombinant Proteins
      • 4.2.1.5. Therapeutic Enzymes
      • 4.2.1.6. Vaccines
      • 4.2.1.7. Blood Factors
    • 4.2.2. Synthetic
  • 4.3. By Potency
    • 4.3.1. Traditional API
    • 4.3.2. HPAPI
  • 4.4. By Manufacturer
    • 4.4.1. Captive APIs
    • 4.4.2. Merchant APIs
  • 4.5. By Type
    • 4.5.1. Generic APIs
    • 4.5.2. Innovative APIs
  • 4.6. By Drugs
    • 4.6.1. Prescription Drugs
    • 4.6.2. Over-the-counter Drugs
  • 4.7. By Usage
    • 4.7.1. Clinical
    • 4.7.2. Research
  • 4.8. By Application
    • 4.8.1. Cardiovascular Diseases
    • 4.8.2. Oncology
    • 4.8.3. CNS and Neurology
    • 4.8.4. Orthopedic
    • 4.8.5. Endocrinology
    • 4.8.6. Pulmonology
    • 4.8.7. Gastroenterology
    • 4.8.8. Nephrology
    • 4.8.9. Ophthalmology
    • 4.8.10. Communicable Diseases
    • 4.8.11. Diabetes
    • 4.8.12. Pain Management
    • 4.8.13. Others
  • 4.9. By Region
    • 4.9.1. North America
    • 4.9.2. Europe
    • 4.9.3. South America
    • 4.9.4. Asia-Pacific
    • 4.9.5. Middle East and Africa
  • 4.10. By Company Market Share (%), 2023

5. Global Active Pharmaceutical Ingredient Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. Value
      • 5.1.1.2. Volume
    • 5.1.2. By Synthesis
      • 5.1.2.1. Biotech
      • 5.1.2.1.1. Monoclonal Antibodies
      • 5.1.2.1.2. Hormones
      • 5.1.2.1.3. Cytokines
      • 5.1.2.1.4. Recombinant Proteins
      • 5.1.2.1.5. Therapeutic Enzymes
      • 5.1.2.1.6. Vaccines
      • 5.1.2.1.7. Blood Factors
      • 5.1.2.2. Synthetic
    • 5.1.3. By Potency
      • 5.1.3.1. Traditional API
      • 5.1.3.2. HPAPI
    • 5.1.4. By Manufacturer
      • 5.1.4.1. Captive APIs
      • 5.1.4.2. Merchant APIs
    • 5.1.5. By Type
      • 5.1.5.1. Generic APIs
      • 5.1.5.2. Innovative APIs
    • 5.1.6. By Drugs
      • 5.1.6.1. Prescription Drugs
      • 5.1.6.2. Over-the-counter Drugs
    • 5.1.7. By Usage
      • 5.1.7.1. Clinical
      • 5.1.7.2. Research
    • 5.1.8. By Application
      • 5.1.8.1. Cardiovascular Diseases
      • 5.1.8.2. Oncology
      • 5.1.8.3. CNS and Neurology
      • 5.1.8.4. Orthopedic
      • 5.1.8.5. Endocrinology
      • 5.1.8.6. Pulmonology
      • 5.1.8.7. Gastroenterology
      • 5.1.8.8. Nephrology
      • 5.1.8.9. Ophthalmology
      • 5.1.8.10. Communicable Diseases
      • 5.1.8.11. Diabetes
      • 5.1.8.12. Pain Management
      • 5.1.8.13. Others
    • 5.1.9. United States*
      • 5.1.9.1. Market Size & Forecast
      • 5.1.9.1.1. Value
      • 5.1.9.1.2. Volume
      • 5.1.9.2. By Synthesis
      • 5.1.9.2.1. Biotech
      • 5.1.9.2.1.1. Monoclonal Antibodies
      • 5.1.9.2.1.2. Hormones
      • 5.1.9.2.1.3. Cytokines
      • 5.1.9.2.1.4. Recombinant Proteins
      • 5.1.9.2.1.5. Therapeutic Enzymes
      • 5.1.9.2.1.6. Vaccines
      • 5.1.9.2.1.7. Blood Factors
      • 5.1.9.2.2. Synthetic
      • 5.1.9.3. By Potency
      • 5.1.9.3.1. Traditional API
      • 5.1.9.3.2. HPAPI
      • 5.1.9.4. By Manufacturer
      • 5.1.9.4.1. Captive APIs
      • 5.1.9.4.2. Merchant APIs
      • 5.1.9.5. By Type
      • 5.1.9.5.1. Generic APIs
      • 5.1.9.5.2. Innovative APIs
      • 5.1.9.6. By Drugs
      • 5.1.9.6.1. Prescription Drugs
      • 5.1.9.6.2. Over-the-counter Drugs
      • 5.1.9.7. By Usage
      • 5.1.9.7.1. Clinical
      • 5.1.9.7.2. Research
      • 5.1.9.8. By Application
      • 5.1.9.8.1. Cardiovascular Diseases
      • 5.1.9.8.2. Oncology
      • 5.1.9.8.3. CNS and Neurology
      • 5.1.9.8.4. Orthopedic
      • 5.1.9.8.5. Endocrinology
      • 5.1.9.8.6. Pulmonology
      • 5.1.9.8.7. Gastroenterology
      • 5.1.9.8.8. Nephrology
      • 5.1.9.8.9. Ophthalmology
      • 5.1.9.8.10. Communicable Diseases
      • 5.1.9.8.11. Diabetes
      • 5.1.9.8.12. Pain Management
      • 5.1.9.8.13. Others
    • 5.1.10. Canada
    • 5.1.11. Mexico

All segments will be provided for all regions and countries covered:

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. South America
    • 5.3.1. Brazil
    • 5.3.2. Argentina
  • 5.4. Asia-Pacific
    • 5.4.1. India
    • 5.4.2. China
    • 5.4.3. Japan
    • 5.4.4. Australia
    • 5.4.5. Vietnam
    • 5.4.6. South Korea
    • 5.4.7. Indonesia
    • 5.4.8. Philippines
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. Synthesis
  • 6.2. Potency
  • 6.3. Manufacturer
  • 6.4. Type
  • 6.5. Drug
  • 6.6. Usage
  • 6.7. Application
  • 6.8. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Pfizer, Inc.
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Abbvie, Inc.
  • 13.3. Novartis AG
  • 13.4. Sanofi S.A.
  • 13.5. F. Hoffmann-La Roche AG
  • 13.6. Bristol-Myers Squibb Company
  • 13.7. Merck & Co., Inc.
  • 13.8. GlaxoSmithKline plc.
  • 13.9. AstraZeneca plc
  • 13.10. Eli Lilly International Corp.
  • 13.11. Teva Pharmaceutical Industries Ltd.
  • 13.12. Boehringer Ingelheim International GmbH
  • 13.13. Johnson & Johnson Services, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
  • Figure 3. Global Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
  • Figure 4. Global Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
  • Figure 5. Global Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
  • Figure 6. Global Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
  • Figure 7. Global Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
  • Figure 8. Global Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
  • Figure 9. Global Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
  • Figure 10. Global Active Pharmaceutical Ingredient Market Share (%), By Region, 2017-2031F
  • Figure 11. North America Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
  • Figure 12. North America Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
  • Figure 13. North America Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
  • Figure 14. North America Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
  • Figure 15. North America Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
  • Figure 16. North America Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
  • Figure 17. North America Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
  • Figure 18. North America Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
  • Figure 19. North America Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
  • Figure 20. North America Active Pharmaceutical Ingredient Market Share (%), By Country, 2017-2031F
  • Figure 21. United States Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
  • Figure 22. United States Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
  • Figure 23. United States Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
  • Figure 24. United States Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
  • Figure 25. United States Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
  • Figure 26. United States Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
  • Figure 27. United States Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
  • Figure 28. United States Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
  • Figure 29. United States Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
  • Figure 30. Canada Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
  • Figure 31. Canada Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
  • Figure 32. Canada Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
  • Figure 33. Canada Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
  • Figure 34. Canada Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
  • Figure 35. Canada Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
  • Figure 36. Canada Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
  • Figure 37. Canada Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
  • Figure 38. Canada Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
  • Figure 39. Mexico Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
  • Figure 40. Mexico Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
  • Figure 41. Mexico Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
  • Figure 42. Mexico Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
  • Figure 43. Mexico Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
  • Figure 44. Mexico Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
  • Figure 45. Mexico Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
  • Figure 46. Mexico Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
  • Figure 47. Mexico Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
  • Figure 48. Europe Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
  • Figure 49. Europe Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
  • Figure 50. Europe Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
  • Figure 51. Europe Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
  • Figure 52. Europe Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
  • Figure 53. Europe Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
  • Figure 54. Europe Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
  • Figure 55. Europe Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
  • Figure 56. Europe Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
  • Figure 57. Europe Active Pharmaceutical Ingredient Market Share (%), By Country, 2017-2031F
  • Figure 58. Germany Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
  • Figure 59. Germany Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
  • Figure 60. Germany Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
  • Figure 61. Germany Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
  • Figure 62. Germany Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
  • Figure 63. Germany Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
  • Figure 64. Germany Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
  • Figure 65. Germany Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
  • Figure 66. Germany Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
  • Figure 67. France Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
  • Figure 68. France Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
  • Figure 69. France Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
  • Figure 70. France Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
  • Figure 71. France Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
  • Figure 72. France Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
  • Figure 73. France Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
  • Figure 74. France Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
  • Figure 75. France Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
  • Figure 76. Italy Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. Italy Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
  • Figure 78. Italy Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
  • Figure 79. Italy Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
  • Figure 80. Italy Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
  • Figure 81. Italy Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
  • Figure 82. Italy Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
  • Figure 83. Italy Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
  • Figure 84. Italy Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
  • Figure 85. United Kingdom Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
  • Figure 86. United Kingdom Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
  • Figure 87. United Kingdom Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
  • Figure 88. United Kingdom Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
  • Figure 89. United Kingdom Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
  • Figure 90. United Kingdom Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
  • Figure 91. United Kingdom Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
  • Figure 92. United Kingdom Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
  • Figure 93. United Kingdom Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
  • Figure 94. Russia Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. Russia Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
  • Figure 96. Russia Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
  • Figure 97. Russia Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
  • Figure 98. Russia Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
  • Figure 99. Russia Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
  • Figure 100. Russia Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
  • Figure 101. Russia Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
  • Figure 102. Russia Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
  • Figure 103. Netherlands Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
  • Figure 104. Netherlands Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
  • Figure 105. Netherlands Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
  • Figure 106. Netherlands Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
  • Figure 107. Netherlands Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
  • Figure 108. Netherlands Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
  • Figure 109. Netherlands Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
  • Figure 110. Netherlands Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
  • Figure 111. Netherlands Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
  • Figure 112. Spain Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
  • Figure 113. Spain Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
  • Figure 114. Spain Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
  • Figure 115. Spain Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
  • Figure 116. Spain Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
  • Figure 117. Spain Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
  • Figure 118. Spain Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
  • Figure 119. Spain Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
  • Figure 120. Spain Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
  • Figure 121. Turkey Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
  • Figure 122. Turkey Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
  • Figure 123. Turkey Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
  • Figure 124. Turkey Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
  • Figure 125. Turkey Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
  • Figure 126. Turkey Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
  • Figure 127. Turkey Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
  • Figure 128. Turkey Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
  • Figure 129. Turkey Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
  • Figure 130. Poland Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
  • Figure 131. Poland Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
  • Figure 132. Poland Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
  • Figure 133. Poland Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
  • Figure 134. Poland Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
  • Figure 135. Poland Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
  • Figure 136. Poland Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
  • Figure 137. Poland Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
  • Figure 138. Poland Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
  • Figure 139. South America Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
  • Figure 140. South America Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
  • Figure 141. South America Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
  • Figure 142. South America Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
  • Figure 143. South America Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
  • Figure 144. South America Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
  • Figure 145. South America Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
  • Figure 146. South America Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
  • Figure 147. South America Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
  • Figure 148. South America Active Pharmaceutical Ingredient Market Share (%), By Country, 2017-2031F
  • Figure 149. Brazil Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
  • Figure 150. Brazil Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
  • Figure 151. Brazil Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
  • Figure 152. Brazil Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
  • Figure 153. Brazil Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
  • Figure 154. Brazil Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
  • Figure 155. Brazil Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
  • Figure 156. Brazil Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
  • Figure 157. Brazil Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
  • Figure 158. Argentina Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
  • Figure 159. Argentina Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
  • Figure 160. Argentina Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
  • Figure 161. Argentina Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
  • Figure 162. Argentina Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
  • Figure 163. Argentina Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
  • Figure 164. Argentina Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
  • Figure 165. Argentina Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
  • Figure 166. Argentina Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
  • Figure 167. Asia-Pacific Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
  • Figure 168. Asia-Pacific Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
  • Figure 169. Asia-Pacific Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
  • Figure 170. Asia-Pacific Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
  • Figure 171. Asia-Pacific Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
  • Figure 172. Asia-Pacific Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
  • Figure 173. Asia-Pacific Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
  • Figure 174. Asia-Pacific Active Pharmaceutical Ingredient Market Share (%), By Usage, In USD Billion, 2016-2030
  • Figure 175. Asia-Pacific Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
  • Figure 176. Asia-Pacific Active Pharmaceutical Ingredient Market Share (%), By Country, 2017-2031F
  • Figure 177. India Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
  • Figure 178. India Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
  • Figure 179. India Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
  • Figure 180. India Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
  • Figure 181. India Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
  • Figure 182. India Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
  • Figure 183. India Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
  • Figure 184. India Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
  • Figure 185. India Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
  • Figure 186. China Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
  • Figure 187. China Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
  • Figure 188. China Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
  • Figure 189. China Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
  • Figure 190. China Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
  • Figure 191. China Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
  • Figure 192. China Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
  • Figure 193. China Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
  • Figure 194. China Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
  • Figure 195. Japan Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
  • Figure 196. Japan Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
  • Figure 197. Japan Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
  • Figure 198. Japan Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
  • Figure 199. Japan Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
  • Figure 200. Japan Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
  • Figure 201. Japan Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
  • Figure 202. Japan Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
  • Figure 203. Japan Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
  • Figure 204. Australia Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
  • Figure 205. Australia Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
  • Figure 206. Australia Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
  • Figure 207. Australia Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
  • Figure 208. Australia Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
  • Figure 209. Australia Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
  • Figure 210. Australia Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
  • Figure 211. Australia Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
  • Figure 212. Australia Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
  • Figure 213. Vietnam Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
  • Figure 214. Vietnam Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
  • Figure 215. Vietnam Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
  • Figure 216. Vietnam Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
  • Figure 217. Vietnam Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
  • Figure 218. Vietnam Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
  • Figure 219. Vietnam Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
  • Figure 220. Vietnam Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
  • Figure 221. Vietnam Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
  • Figure 222. South Korea Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
  • Figure 223. South Korea Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
  • Figure 224. South Korea Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
  • Figure 225. South Korea Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
  • Figure 226. South Korea Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
  • Figure 227. South Korea Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
  • Figure 228. South Korea Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
  • Figure 229. South Korea Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
  • Figure 230. South Korea Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
  • Figure 231. Indonesia Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
  • Figure 232. Indonesia Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
  • Figure 233. Indonesia Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
  • Figure 234. Indonesia Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
  • Figure 235. Indonesia Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
  • Figure 236. Indonesia Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
  • Figure 237. Indonesia Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
  • Figure 238. Indonesia Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
  • Figure 239. Indonesia Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
  • Figure 240. Philippines Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
  • Figure 241. Philippines Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
  • Figure 242. Philippines Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
  • Figure 243. Philippines Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
  • Figure 244. Philippines Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
  • Figure 245. Philippines Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
  • Figure 246. Philippines Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
  • Figure 247. Philippines Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
  • Figure 248. Philippines Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
  • Figure 249. Middle East & Africa Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
  • Figure 250. Middle East & Africa Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
  • Figure 251. Middle East & Africa Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
  • Figure 252. Middle East & Africa Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
  • Figure 253. Middle East & Africa Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
  • Figure 254. Middle East & Africa Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
  • Figure 255. Middle East & Africa Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
  • Figure 256. Middle East & Africa Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
  • Figure 257. Middle East & Africa Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
  • Figure 258. Middle East & Africa Active Pharmaceutical Ingredient Market Share (%), By Country, 2017-2031F
  • Figure 259. Saudi Arabia Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
  • Figure 260. Saudi Arabia Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
  • Figure 261. Saudi Arabia Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
  • Figure 262. Saudi Arabia Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
  • Figure 263. Saudi Arabia Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
  • Figure 264. Saudi Arabia Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
  • Figure 265. Saudi Arabia Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
  • Figure 266. Saudi Arabia Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
  • Figure 267. Saudi Arabia Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
  • Figure 268. UAE Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
  • Figure 269. UAE Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
  • Figure 270. UAE Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
  • Figure 271. UAE Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
  • Figure 272. UAE Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
  • Figure 273. UAE Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
  • Figure 274. UAE Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
  • Figure 275. UAE Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
  • Figure 276. UAE Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
  • Figure 277. South Africa Active Pharmaceutical Ingredient Market, By Value, In USD Billion, 2017-2031F
  • Figure 278. South Africa Active Pharmaceutical Ingredient Market, By Volume, In Millions, 2017-2031F
  • Figure 279. South Africa Active Pharmaceutical Ingredient Market Share (%), By Synthesis, 2017-2031F
  • Figure 280. South Africa Active Pharmaceutical Ingredient Market Share (%), By Potency, 2017-2031F
  • Figure 281. South Africa Active Pharmaceutical Ingredient Market Share (%), By Manufacturer, 2017-2031F
  • Figure 282. South Africa Active Pharmaceutical Ingredient Market Share (%), By Type, 2017-2031F
  • Figure 283. South Africa Active Pharmaceutical Ingredient Market Share (%), By Drug, 2017-2031F
  • Figure 284. South Africa Active Pharmaceutical Ingredient Market Share (%), By Usage, 2017-2031F
  • Figure 285. South Africa Active Pharmaceutical Ingredient Market Share (%), By Application, 2017-2031F
  • Figure 286. By Synthesis Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 287. By Potency Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 288. By Manufacturer Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 289. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 290. By Drug Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 291. By Usage Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 292. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 293. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023